PLUS THERAPEUTICS PSTV 深 沪
等待开盘 11-03 09:30:00 美东时间
0.543
+0.013
+2.45%
华盛通- 最 高0.5476
- 今 开0.5212
- 成交量 657.87万股
- 最 低 0.486
- 昨 收 0.53
- 总市值 2769.22万
- 52周最高 2.3099
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.1634
- 委 比 -99.01%
- 总股本 5099.85万
- 历史最高 343.35
- 量 比 0.99
- 振 幅 11.62%
- 历史最低 0.1634
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics Q3 EPS $(0.04) Misses $(0.02) Estimate, Sales $1.397M Miss $1.500M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 89.19 percent increase over losses of $(0.37) per share from
10-31 04:28
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $5 price target.
10-21 20:28
Plus Therapeutics Signs Lease Agreement in Houston
An update from Plus Therapeutics ( ($PSTV) ) is now available. On October 16, 2...
10-21 19:50
Plus Therapeutics Expands CNSide Diagnostic Business, Lands National Coverage Deal With UnitedHealthcare
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,
10-21 19:42
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $21
Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and raises the price target from $20.5 to $21.
10-06 18:07
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
CNSide Diagnostics, a subsidiary of Plus Therapeutics, Inc., has signed a national agreement with UnitedHealthcare to provide the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration test to over 51 million people in the U.S. The CNSide® CSF Assay Platform aids in rapid diagnoses, treatment monitoring, and guidance for patients with leptomeningeal metastases. Already, over 11,000 tests have been conducted at U.S. cancer institutions since 2020, ach...
09-25 11:30
Plus Therapeutics Secures Additional $1.9M CPRIT Payment Under $17.6M Non-Dilutive Grant
Non-dilutive payment is part of $17.6 million award granted for the Company's leptomeningeal cancer targeted radiotherapeutic development programHOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.
09-22 19:32
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT
Plus Therapeutics received a $1.9 million non-dilutive payment from the Cancer Prevention and Research Institute of Texas (CPRIT), part of a $17.6 million grant for its leptomeningeal cancer radiotherapeutic program. This is the second non-dilutive financing from CPRIT, following a $1.6 million payment in July 2025. The funding supports clinical development of REYOBIQ™ for the ReSPECT-LM trial and advances the CNSide LM diagnostic test. Plus Ther...
09-22 11:30
